Skip to content

PHARMACIE JOSAPHAT

Active Private limited companyfounded 2006active for 20 yearsLouis Bertrandlaan 73, 1030 SchaerbeekKBO/BCE: BE 0879.137.625

Lifetime

20 annual accounts with figures on one time axis
peak of €121,919 in 2017
€115,565▲ 50.5%
lowest -€68,617 in 2019
€29,602▲ 19.6%
peak of €185,268 in 2018
€123,522▲ 31.5%
€175,302▼ 6.2%
Board2 names since 2023
2 directors and 1 other
Documentsfilings and deeds
25-09-202656 days late
2025micro format
Gross margin from €76,799 to €115,565Equity from €93,920 to €123,522Cash from €57,465 to €27,193

Key points

from the 2025 annual accounts

Turnover

≈ €400,000 estimated

The micro format states no turnover.

Filings

20 annual accounts since 2006
AprilJune31 JulyOctober2010201520202025

Eight of the last ten came late. The 2021 accounts came in latest, 141 days after the end of the period.

Position in the sector

€29,602

Higher net result than 80% of companies in retail trade. The sector median is €4,724, over 25,399 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,388 companies had the same profile as PHARMACIE JOSAPHAT has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,388 companies, not a prediction for PHARMACIE JOSAPHAT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
Director,
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0879137625
1 director resigning, 1 reappointment resigns · reappointed as director · acts as permanent representative · General meeting of 29-11-2023 · Gazette deed
1 manager appointed, 2 resignations (manager) and (manager) resign · appointed as manager · Discharge granted to · General meeting of 29-06-2023 · Gazette deed
appointed as manager General meeting of 02-04-2019 · Gazette deed
All 34 events

Comparable companies

same main activity, similar in size and age
Company
PHARMACIE JOSAPHAT Schaerbeek €298,824 €115,565 41.3% -
PHARMACIE DE BROUCKERE Brussels €300,319 €132,060 0.6% 1.5
PHARMACIE DE RIENNE Gembloux €334,259 €109,643 62.4% -
APOTHEEK DE RIDDER Dendermonde €319,273 €102,207 46.4% -
POGGE Schaerbeek €285,910 €128,031 34.5% 2
MEDPHAR Schaerbeek €255,858 €113,640 25.6% -
I & CM MARBOTIN Schaerbeek €323,588 €152,686 29.2% -

These companies have the same main activity as PHARMACIE JOSAPHAT: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €256,000 and €334,000, founded between 2001 and 2006.

Official details

Source: KBO
Status
Active since 03-02-2006Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 2 others
Establishment unit
2.152.262.7241030 Schaerbeek, since 16-03-2006
Financial year end
31 December
Peppol
Reachable since 09-01-2026
Company details

Annual accounts 2025

€298,824▲ 6.4%
Filing
Filed on 25-09-2026
Financials

Insights on PHARMACIE JOSAPHAT

PHARMACIE JOSAPHAT files the micro format. That format states no turnover. The gross margin rose from €76,691 in 2007 to €115,565 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHARMACIE JOSAPHAT

What is the company number of PHARMACIE JOSAPHAT?
The company number of PHARMACIE JOSAPHAT is 0879.137.625. The VAT number is the same number with BE in front: BE 0879.137.625.
Where is PHARMACIE JOSAPHAT based?
The registered office is at Louis Bertrandlaan 73, 1030 Schaerbeek.Company details
What does PHARMACIE JOSAPHAT do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARMACIE JOSAPHAT?
PHARMACIE JOSAPHAT is a private limited company (BV).
When was PHARMACIE JOSAPHAT founded?
PHARMACIE JOSAPHAT was founded on 03-02-2006.
Is PHARMACIE JOSAPHAT still active?
Yes, PHARMACIE JOSAPHAT is an active enterprise in the KBO register.
What is the turnover of PHARMACIE JOSAPHAT?
The turnover in financial year 2025 is about €400,000. This figure is estimated from the gross margin of €115,565 and 37 comparable companies (NACE 477). It probably lies between €300,000 and €680,000.Financials
Is PHARMACIE JOSAPHAT profitable?
In financial year 2025, PHARMACIE JOSAPHAT made a profit of €29,602.
Where can I find the annual accounts of PHARMACIE JOSAPHAT?
PHARMACIE JOSAPHAT filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMACIE JOSAPHAT due?
PHARMACIE JOSAPHAT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.